The problems of formations of drug resistance M.tuberculosis and the possibilities of the respiratory fluoroquinolones Sparfloxacin
Abstract
In this review you can find data about tuberculosis mycobacterium resistance mechanisms to antibiotics. The data include molecular action mechanism, main pharmacokinetic characteristics and side effects of Sparfloxacin. The question of Sparfloxacin application in MDR-TB treatment is discussed in this article.
About the Authors
E. N. Kareva
ГБОУ ВПО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России
Russian Federation
Russian Federation
E. M. Bogorodskaya
ГКУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
References
1. Лазарева Н.Б., Хайменова Т.Ю., Хайменов А.Я. Роль респираторных фторхинолонов в лечении туберкулеза лeгких при неэффективности препаратов первой линии // Антибиотики и химиотерапия. – 2008. – № 53 (5/6). – С. 14-20.
2. Падейская Е.Н. Спарфлоксацин - антибактериальный препарат широкого спектра действия // Рус. мед. журн. – 2002. – № 10 (3). – (Инфекции. Иммунология. Аллергология).
3. Соколова Г.Б., Хайменова Т.Ю., Лазарева Я.В., Хайменов А.Я. Спарфлоксацин в комплексной терапии туберкулeза лeгких// Антибиотики и химиотерапия. – 2008. – № 53 (5/6). – С. 21-27.
4. Степашин Ю.Г., Степашина В.Н., Шемякин И.Г. Молекулярные механизмы устойчивости микобактерии туберкулеза к лекарственным препаратам // Антибиотики и химиотерапия. – 1999. – № 4. – С. 39-43.
5. Aubry A., Pan X.S., Fisher L.M. et al. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity //Antimicrob. Agents Chemother. – 2004. – Vol. 48. – N. 4. – P. 1281-1288.
6. Balganesh T.S., Alzari P.M., Cole S.T. Rising standards for tuberculosis drug development // Trends in Pharmacol. Sci. – 2008. – Vol. 29. – N. 11. – P. 576-581.
7. Bolhuis M.S., Panday P.N., Pranger A.D. et al. Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams // Pharmaceutics. – 2011. – Vol. 3. – P. 865-913.
8. Dwyer D.J., Kohanski M.A., Hayete B., Collins J.J. Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli // Mol. Syst. Biol. – 2007. – Vol. 3. – P. 91. Published online 2007 March 13. doi: 10.1038/msb4100135.
9. Global overview of new anti-TB compounds / Proceedings of the 17th Eur. Congr. of Clin. Microbiol. Infect. Dis. and 25th Int. Congr. of Chemotherapy. – 2007.
10. http://genolist.pasteur.fr/TubercuList
11. http://www.who.int/tdr/
12. Huang C.S., Wu C.C. Observation of the clinical efficacy of sparfloxacin in the treatment of multiple drug resistance pneumonial tuberculosis // Chinese J. Antibiotics. – 2000. – Vol. 25. – N. 4. – P. 302–303.
13. Ji Y.M., Dong L.H., Wang Q., Yu W.Q. Short-term observation of curative effects in treatment of multiple-drug resistance pulmonary tuberculosis with sparfloxacin and ofloxacin // J. Postgrad. Med. – 2001. – Vol. 24. – N. 7. – P. 32–33.
14. Kawahara S., Tada A., Nagare H. Clinical evaluation of new quinolones as antituberculosis drugs // Kekkaku. – 1999. – Vol. 74. – N. 1. – P. 71-75.
15. Lalande V., Truffot-Pernot C.H., Paccaly-Moulin A., Grosset J. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice // Antimicrob. agents and chemother. – 1993. – Vol. 37. – N. 3. – P. 407-413.
16. Lenaerts A.J., De Groote M.A., Orme I.M. Preclinical testing of new drugs for tuberculosis: current challenges // Trends in Microbiology. – 2008. – Vol. 16. – N. 2. – P. 48-54.
17. Lubasch A., Erbes R., Mauch H., Lode H. Sparfoxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy // Eur. Resp. J. – 2001. - Vol. 17. – P. 641-646.
18. Mitchison D., Davies G. The chemotherapy of tuberculosis: past, present and future // Int. J. Tuberc. Lung Dis. – 2012. – Vol. 16. – N. 6. – P. 724-732.
19. Pranger A.D., Alffenaar J.W.C., Aarnoutse R.E. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach // Current Pharmaceutical Design. – 2011. – Vol. 17. – N. 27. – P. 2900-2930.
20. Shandil R.K., Jayaram R., Kaur P. et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy // Antimicrob. Agents Chemother. – 2007. – Vol. 51. – N. 2. – P. 576–582.
21. Singh M., Chauhan D.S., Gupta P. et al. In vitro effect of fluoroquinolones against Mycobacterium tuberculosis isolates from Agra & Kanpur region of north India // Indian J. Med. Res. – 2009. – Vol. 129. – P. 542-547.
22. Singla R., Gupta S., Gupta R., Arora V.K. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results // Int. J. Tuberc. Lung Dis. – 2001. – Vol. 5, N. 6. – P. 559-563.
23. Struwe M., Greulich K.O., Perentes E. et al. // J. Invest. Dermatol. – 2009. – Vol. 129. – N. 3. – P. 699-704.
24. Sukhesh R.A.O. Uncontrolled trial of sparfloxacin in retreatment of pulmonary tuberculosis // Respirology. – 2004. – Vol. 9. – N. 3. – P. 402–405.
25. Sun W., Wenyi C., Cunzhi L. et al. A randomized controlled study of sparfloxacin and ofloxacin in the treatment of multiple drug resistant pulmonary tuberculosis // Chinese J. Antibiotics. – 2000. – Vol. 25. – N. 1. – P. 52–54.
26. Wade M.M., Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis // Front. Biosci.- 2004. – Vol. 9. – P. 975–994.
27. Wei S., Wenyi C., Cunzhi L.et al. A randomized controlled study of sparfloxacin and ofloxacin in the treatment of multiple drug resistant pulmonary tuberculosis // Chinese J. Antibiotics. – 2000. – Vol. 25. – N. 1. – P. 53–55.
28. Zhang Z., Lu J., Wang Y. et al. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China // Antimicrob. Agents Chemother. – 2014. – Vol. 58. – N. 1. – P. 364-369.
29. Ziganshina L.E., Squire S.B. Fluoroquinolones for treating tuberculosis: review // The Cochrane Library. – 2009. – Issue 1. – http://www.thecochranelibrary.com
Review
For citations:
Kareva E.N., Bogorodskaya E.M. The problems of formations of drug resistance M.tuberculosis and the possibilities of the respiratory fluoroquinolones Sparfloxacin. Tuberculosis and socially significant diseases. 2015;(1):67-74. (In Russ.)
Views:
29
Email this article 